Gereguleerd
Vroeg verkopen mogelijk
- Risiconiveau
- Hoogste
- Risico-rendement
- Gemiddeld
- Starten vanaf
- €500
Financiering gesloten op 20 Sep 2026. De pagina blijft online ter informatie; vergelijkbare open projecten staan hieronder.
Kairos Discovery
Frankrijk
A Lyon-based biotech developing KDX-350, an oral bivalent CK2 inhibitor for colorectal and clear-cell renal cancer, to license to a pharmaceutical partner from 2027.
Kerncijfers
- Verwacht rendement
- tot 20×
- schatting van het platform
- Waardering
- €3,294,118
- Aangeboden belang
- 21
- Verwachte exit
- 2030
- Financiering eindigt
- 20 Sep 2026
- Starten vanaf
- €1,000
- Doelbedrag
- €850,000
Wat u bezit, hoe het kan opbrengen, en wanneer
Wat bezit ik?
21 van het bedrijf
Kijk in de documenten hoe de aandelen worden gehouden en welke rechten ze geven.
Hoe kan het opbrengen?
Het platform schat tot 20×
Meestal alleen als het bedrijf wordt verkocht of naar de beurs gaat. Schattingen zijn beweringen van het platform zelf.
Wanneer zou ik geld kunnen krijgen?
Rond 2030
Alleen als er een verkoop of beursgang komt; daarvoor zijn aandelen moeilijk te verkopen.
Kapitaal loopt risico. De meeste start-ups mislukken; schattingen zijn beweringen van het platform zelf. Aandelen zijn moeilijk te verkopen vóór een exit.
Zou de AI investeren?
AI 63 GemiddeldOnze AI geeft dit project 63 van de 100: Gemiddeld. Zo werkt de AI-score
Informatie, geen persoonlijk beleggingsadvies. De AI-score beoordeelt de documenten die het platform publiceert, kan onjuist zijn en voorspelt geen rendement.
AI-analyse
AIKairos Discovery — Crowdfunding Investor Memo
A French laboratory company designing an experimental cancer medicine that it plans to sell or license to a large pharmaceutical company rather than sell to patients itself.
Sector: Biotechnology (preclinical oncology) · Stage: Seed (preclinical) · HQ: Lyon, France · Raise: €850,000 target (maximum €1,500,000)
Snapshot
|
1 · Is the price fair? 💶 |
5 / 5 — Supported. At €2.8M–€3.3M before this round, the price is below every European early-stage benchmark we located: a median of €5.0M in Q3 2025 and €3.6M over the longer term (PitchBook-derived data, November 2025), a typical seed range of €4M–€12M (Startkeel, 2026), and a European early-stage median of $6.54M for 2020–2025 (Equidam, Q3 2025). |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 63 / 100 — Average The strongest evidence is the people and the science: the chairman led a comparable Lyon company to an acquisition by Eli Lilly in 2023, and the underlying research is published in a peer-reviewed chemistry journal with a crystal structure deposited in a public database. The biggest gap is that the medicine being offered here, KDX-350, is not the compound described in that publication, and no data on KDX-350 itself is in the pack we reviewed. |
|
3 · If they do, what could it pay? 🎯 |
Target 20x over 3.5–4.5 years (the company's own plan; the standard expectation for a seed-stage company is about 10x over 5–7 years). If reached, illustratively 5x–50x before fees and before future dilution. Method: the required sale value divided by the €4.09M value of the whole company at this round's price. The low end is a licensing deal at the median upfront payment for a preclinical cancer drug, $22M (Ambrosia Ventures deal database, 2026); the high end is the company's own stated target of more than €200M once the medicine has shown early results in patients. |
How to read the score
|
85–100 · Excellent |
All key preconditions for reaching an exit stage are evidenced and strong — rare at this stage |
|
70–84 · Good |
Preconditions largely in place, with specific gaps — named in the questions section |
|
50–69 · Average |
Meaningful preconditions missing or weakly evidenced |
|
30–49 · Weak |
Several core preconditions absent, or the evidence points against them |
|
1–29 · Critical |
Fundamental preconditions are not visible in the evidence |
|
What we could check. We checked 33 of the company's claims against public sources. The company registration, its 2023 fundraise, the chairman's previous sale of a business to Eli Lilly, the patent family, the peer-reviewed publication and the French tax ruling all check out against public records. The figures for the medicine itself (KDX-350), the letter of interest from a pharmaceutical company, the current cash position and most of the market-size numbers rest on the company's own materials — see the questions section. Your money is locked in. Crowdfunding shares normally cannot be sold early — expect your money to be tied up for several years, until the company is sold or a similar event happens. |
Three answers, one honest note. The fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the building blocks in place to reach a point where a sale or licensing deal can happen — it audits readiness on the evidence disclosed. It is not a measure of how likely success is, and even companies with every building block in place fail more often than they succeed, which is why this kind of investing only works as a small part of a spread-out portfolio. The returns range is an illustration built from named industry benchmarks, not a forecast. Where something was not in the pack we reviewed, it did not lower any score — it appears in the questions list instead, so you can ask the company directly before you invest. The listing was reviewed by a licensed crowdfunding platform before it went live. Nothing here is a recommendation.
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
|
Deal terms. No terms were identified in the reviewed documents that would prevent a crowdfund investor from sharing in the upside. Full mechanics are at the end of this memo. One point to check: the two platform documents disagree on a single right. The official Key Investment Information Sheet states there is no prio… |
De volledige analyse behandelt de lener of het bedrijf, de zekerheid, de kasstroom, de risico's en een oordeel. Log in om deze te lezen.
Informatie, geen persoonlijk beleggingsadvies. De AI-score beoordeelt de documenten die het platform publiceert, kan onjuist zijn en voorspelt geen rendement.
Vraag de AI over dit project
Log in om de AI vragen te stellen over de documenten van dit project.
InloggenSpreekt dit project u aan?
👍 Ja · 0 👎 Nee · 0
Reacties · 0
- Nog geen reacties.
Het platform en vergelijkbare projecten
Aangeboden op
Vergelijkbare open projecten
Kepplair Evolution
Sowefund
- Verwacht rendement
- tot 7×
- schatting van het platform
- Waardering
- €60,000,000
Doel: €9m
Vanaf €500
Bekijk project
Wind Fisher
Sowefund
- Verwacht rendement
- tot 10×
- schatting van het platform
- Waardering
- €9,961,800
Doel: €600k
Vanaf €1,000
Bekijk project
Blumana
Sowefund
- Verwacht rendement
- tot 28×
- schatting van het platform
- Waardering
- €2,799,571
Doel: €750k
Vanaf €1,000
Bekijk project